SANTA CLARA, California, February 29 /PRNewswire/ --

Finesse Solutions, LLC and Applikon Biotechnology Inc, announced the general release of the TruConnect(TM) gateway, a migration device designed to provide an interface between Applikon ADI 1010 and ADI 1030 Controllers, and the Finesse TruLogic(TM) Controller, enabled by Finesse's TruBio(TM) software (based on DeltaV(TM) control.)

TruConnect(TM) gateways harmonize an installed base of different ADI bioreactor controllers onto the same DeltaV(TM) control system platform. This harmonization can be made in phases, in order to lower budgetary costs and operating risk by leveraging three versions of TruBio(TM) software: TruBio(TM) Monitor for data collection only; TruBio(TM) SCADA for supervisory control; and TruBio(TM) OS for truly "active" control.

With TruBio(TM) software, end users can reduce their operators' learning curve with a uniform, intuitive user interface, increase flexibility with an open, fully configurable system, and improve efficiency with save/load replication of set-points and control loop parameters.

Applikon's President, John Chory, stated "The collaboration with Finesse has enabled us to ensure our customers that their substantial investment in our control products over the years can be easily migrated to an Applikon supported DeltaV solution whenever they require."

About Finesse Solutions, LLC

California-based Finesse Solutions, LLC, leads the way in developing new measurement and control technologies, in order to enable the transition to single-use systems, bring new capabilities to existing bioreactor platforms, and harmonize global bio-process information transfer. Our current product family provides comprehensive measurement and control solutions for upstream processes in the biotech and pharmaceutical industries. For more information, please visit us at http://www.finesse.com

About Applikon

Applikon is a privately owned Netherlands based company of which the Biotechnology division develops, manufactures and supplies bioreactor and control systems for research, pilot scale, and production. Founded in 1973, Applikon has grown into a global enterprise capable of supplying a broad and diverse line of bioreactor and control systems. Applikon autoclavable bioreactor systems are the worldwide industry standard. Applikon controllers comply with the highest standards applied in the pharmaceutical industry. AppliSens, owned by Applikon, presents sensors and perfusion systems for application in bio-processes under GMP conditions.

Applikon is headquartered in Schiedam, the Netherlands, with major operations in Foster City (USA), Eckington (UK), and in more than 12 countries. For more information refer to http://www.applikon.com.

Web site: http://www.finesse.com http://www.applikon.com

Kimberly Lozada of Finesse Solutions, LLC, +1-408-327-6613